Your browser is no longer supported. Please, upgrade your browser.
OPNT Opiant Pharmaceuticals, Inc. daily Stock Chart
Opiant Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.41 Insider Own4.80% Shs Outstand2.63M Perf Week6.97%
Market Cap45.60M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.14M Perf Month-13.26%
Income-2.10M PEG- EPS next Q- Inst Own4.20% Short Float4.94% Perf Quarter-23.38%
Sales15.60M P/S2.92 EPS this Y-89.30% Inst Trans15.71% Short Ratio2.81 Perf Half Y-47.57%
Book/sh5.13 P/B3.38 EPS next Y- ROA- Target Price- Perf Year158.81%
Cash/sh4.30 P/C4.04 EPS next 5Y- ROE- 52W Range5.00 - 51.90 Perf YTD-24.51%
Dividend- P/FCF- EPS past 5Y15.40% ROI10.50% 52W High-66.59% Beta-0.23
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low246.80% ATR0.83
Employees3 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)42.19 Volatility6.00% 4.06%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume1.49 Prev Close16.56
ShortableYes LT Debt/Eq0.00 EarningsMar 29 Payout- Avg Volume37.64K Price17.34
Recom- SMA20-6.26% SMA50-11.17% SMA200-33.90% Volume56,007 Change4.71%
May-15-18 10:35AM  OPNT: KOL Event Highlights Medications for Addictions and Related Disorders Zacks Small Cap Research
May-08-18 04:05PM  Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
May-03-18 08:00AM  Opiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related Disorders GlobeNewswire
Apr-20-18 07:30AM  Blog Exposure - Opiant Pharma Receives Grant for Development of OPNT003 for Treatment of Opioid Overdose ACCESSWIRE
Apr-18-18 08:00AM  Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose GlobeNewswire
Apr-03-18 08:00AM  Investor Expectations to Drive Momentum within Atrion, Curis, Independence Contract Drilling, Utah Medical Products, FutureFuel, and Opiant Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Mar-22-18 07:00AM  Free Research Report as HubSpots Quarterly Earnings Surpassed Analysts Estimates ACCESSWIRE
Mar-21-18 10:45AM  OPNT: Opiant Developing New Opioid Overdose Treatment Zacks Small Cap Research -10.06%
Mar-19-18 05:54PM  Trump says he is working to lower prescription drug prices Reuters +27.55%
05:04PM  As U.S. opioid crisis grows, Trump calls for death penalty for dealers Reuters
04:05PM  Opiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference GlobeNewswire
Mar-07-18 04:05PM  Opiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update GlobeNewswire
Feb-22-18 08:00AM  Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications GlobeNewswire
Feb-13-18 12:00PM  OPNT: Developing Longer-Acting Opioid Overdose Treatment Zacks Small Cap Research +23.82%
Feb-12-18 08:00AM  Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose GlobeNewswire
Feb-08-18 08:00AM  Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid Overdose GlobeNewswire +7.89%
Feb-01-18 07:40AM  Report: Exploring Fundamental Drivers Behind Bryn Mawr Bank, Utah Medical Products, Opiant Pharmaceuticals, Whiting Petroleum, International Business Machines, and QUALCOMM New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-02-18 04:01PM  Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants GlobeNewswire
Dec-31-17 01:45PM  Insider Q&A: Narcan exec talks merits of spray for overdoses Associated Press
Dec-20-17 02:30PM  OPNT: Will Begin Receiving 90% of NARCAN® Nasal Spray Royalties in 1Q18 Zacks Small Cap Research +30.51%
08:00AM  Opiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN® Nasal Spray for Opioid Overdose GlobeNewswire
Dec-19-17 10:30AM  OPNT: News Surrounding Opioid Crisis Shows Need Still High for NARCAN® Nasal Spray Zacks Small Cap Research
10:00AM  Opiant Pharmaceuticals (Nasdaq: OPNT) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
08:00AM  Opiant Pharmaceuticals to Ring The Nasdaq Opening Bell on December 20, 2017 GlobeNewswire
Dec-18-17 08:00AM  Opiant Pharmaceuticals Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine GlobeNewswire -15.52%
Dec-07-17 10:26AM  Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q1, 2018 By the Numbers : December 7, 2017 Capital Cube
Dec-04-17 04:05PM  Opiant Pharmaceuticals, Inc. Reports Fiscal First Quarter 2018 Financial Results GlobeNewswire
Oct-17-17 08:33AM  Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q4, 2017 By the Numbers : October 17, 2017 Capital Cube +6.17%
Oct-16-17 03:00PM  OPNT: Looking to Keep Momentum Going into Fiscal 2018 Zacks Small Cap Research -11.27%
Oct-13-17 07:17PM  Is It Time To Buy Opiant Pharmaceuticals Inc (OPNT) Based Off Its PE Ratio? Simply Wall St. +5.18%
07:00AM  Opiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update GlobeNewswire
Oct-04-17 07:20AM  Corporate News Blog - Titan Pharma and Opiant Pharma Collaborate to Discover a New Approach for Treatment of Opioid Use Disorder ACCESSWIRE +8.49%
Oct-02-17 07:00AM  Titan Pharmaceuticals and Opiant Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder Treatment PR Newswire -5.44%
07:00AM  Opiant Pharmaceuticals and Titan Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder Treatment GlobeNewswire
Sep-25-17 07:00AM  Opiant Pharmaceuticals, Inc., CEO Roger Crystal, M.D., to Present to President's Commission on Combating Drug Addiction and the Opioid Crisis GlobeNewswire -5.30%
Sep-20-17 12:22PM  Opiant Up Nearly 30% On Favorable Zacks Report Forbes
Sep-19-17 10:00AM  OPNT: Estimating When Royalties to NARCAN® Nasal Spray Revert Back to Opiant Zacks Small Cap Research +29.54%
Sep-18-17 07:00AM  Corporate News Blog - Opiant Delivers Update on NARCAN Nasal Spray; Surpasses $25 Million Net Sales in H1 2017 ACCESSWIRE +14.28%
Sep-15-17 07:00AM  Opiant Pharmaceuticals, Inc. Provides an Update on NARCAN® Nasal Spray GlobeNewswire -9.98%
Sep-06-17 07:00AM  Opiant Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire +17.52%
Sep-05-17 07:00AM  Opiant Pharmaceuticals, Inc. Announces Appointment of David OToole as Chief Financial Officer GlobeNewswire
Aug-29-17 03:00PM  OPNT: Uplists to NASDAQ Zacks Small Cap Research +17.76%
Aug-28-17 07:00AM  Opiant Pharmaceuticals, Inc. Announces Listing on the Nasdaq Capital Market GlobeNewswire +12.34%
Aug-14-17 07:00AM  Opiant CEO Roger Crystal Appears on Fox News Channel to Discuss the Opioid Crisis Being Declared a National Emergency GlobeNewswire +17.69%
Aug-10-17 01:00PM  OPNT: Receives Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization Zacks Small Cap Research -23.84%
07:00AM  Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization GlobeNewswire
Aug-04-17 07:00AM  Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent GlobeNewswire
Jul-28-17 06:51PM  Opiant Pharmaceuticals Looks to Create a Heroin Vaccine and Treat Addictions -21.51%
Jul-27-17 08:44AM  Opiant CEO Roger Crystal Appears on Fox & Friends GlobeNewswire +27.41%
Jul-26-17 01:14PM  Opiant CEO Roger Crystal Appears on Fox Business Network GlobeNewswire +24.73%
Jul-19-17 03:15PM  OPNT: Encouraging Data From P1 Study of OPNT002 in Alcohol Use Disorder Zacks Small Cap Research
07:00AM  Opiant Pharmaceuticals, Inc. Announces Phase I Data for OPNT002 in Development for the Treatment of Alcohol Use Disorder GlobeNewswire
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.